Ovarian cancer
Despite being one of the most lethal cancers, ovarian cancer has often been overlooked. However, advances in understanding of the disease have begun to yield improvements in care.
This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge the financial support of GlaxoSmithKline in producing this Outlook. The sponsor retains the sole responsibility for the following message.
Each year over 300,000 women worldwide are diagnosed with ovarian cancer. Because ovarian cancer is difficult to detect at an early stage, and symptoms such as abdominal bloating, weight loss, fatigue, back pain, and pelvic discomfort are nonspecific, most women (approximately 8 out of 10) are not diagnosed until the cancer is advanced and has spread to other sites in the body. Advanced ovarian cancer is difficult to treat and is associated with poor outcomes.
GlaxoSmithKline (GSK) is a science-led global healthcare company dedicated to helping people do more, feel better, and live longer. As part of GSK’s unyielding commitment to address the unmet needs of patients with cancer, they are focused on exploring innovative treatment approaches, driving development of novel therapies, and continually advancing the therapeutic landscape. To improve treatment options and outcomes for patients with ovarian cancer, GSK is exploring 4 key areas of research: tumor cell targeting, synthetic lethality, immuno-oncology, and oncology cell therapy.
